


Outpatient Treatment Options for COVID-19 with Mild to Moderate Symptoms (Age 12+)



Outpatient Treatment Options for COVID-19

	Nirmatrelvir-ritonavir [Paxlovid]	Remdesivir	Molnupiravir [Lagevrio]
Approval/Availability Status	Granted EUA COVID-19 Therapeutic Locator	FDA Approved	Granted EUA COVID-19 Therapeutic Locator
Dosing	Nirmatrelvir 300mg (two 150mg tabs) + ritonavir 100mg (one 100mg tab) BID x 5 days (total of 30 tabs) For eGFR ≥ 30 to < 60 mL/min: Nirmatrelvir 150mg (one 150mg tab) + ritonavir 100mg (one 100mg tab) BID x 5 days (total of 20 pills)	200mg IV on day 1, 100mg IV on days 2-3	800mg (four 200mg tabs) BID x 5 days (total of 40 tabs)
Eligibility	12+ At risk for severe disease	12+ At risk for severe disease	18+ At risk for severe disease
Timing of Initiation of Medication	Symptom onset ≤ 5 days	Symptom onset ≤ 7 days	Symptom onset ≤ 5 days
Contraindications/Special Considerations	<ul style="list-style-type: none"> Hypersensitivity to ritonavir/any component Co-administration with drugs highly dependent on CYP3A eGFR < 30 mL/min 	<ul style="list-style-type: none"> Hypersensitivity to remdesivir/any component eGFR < 30 mL/min: Manufacturer does not recommend use; however, benefits may outweigh risks; significant toxicity with a short duration of therapy is unlikely 	<ul style="list-style-type: none"> Pregnancy Contraceptive considerations*
Drug Interactions	Contraindications with astemizole, depirdil, fusidic acid, neratinib, rivaroxaban, salmeterol, terfenadine, vardenafil, venetoclax, voriconazole <ul style="list-style-type: none"> Check ALL drug interactions 	Chloroquine, CYP3A4 inducers, hydroxychloroquine	Cladribine
Mechanism of Action	Protease inhibitor	Inhibits viral replication	Induces error in viral RNA replication
Reported Effectiveness Reduction Hospitalization	88% for hospitalization; 99% for death	87% for hospitalization	30% for hospitalization

*Patients who may become pregnant should use reliable contraception correctly and consistently during therapy and for 4 days after the last dose of Molnupiravir. Males with partners who may become pregnant should also use effective contraception during therapy and for at least 3 months after the last Molnupiravir dose.